In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Applied Genetic Technologies (AGTC – Research Report), with a price target of $24.00. The company’s shares closed last Tuesday at $0.73, close to its 52-week low of $0.58.
According to TipRanks.com, Pantginis has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -27.6% and a 21.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Bioline RX Ltd Sponsored ADR, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
Applied Genetic Technologies has an analyst consensus of Strong Buy, with a price target consensus of $12.25.
The company has a one-year high of $4.21 and a one-year low of $0.58. Currently, Applied Genetic Technologies has an average volume of 503.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Applied Genetic Technologies Corp. engages in the development of gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. It has clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL.
Read More on AGTC: